Literature DB >> 30355619

The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Anne Monks1, Yingdong Zhao2, Curtis Hose1, Hossein Hamed2, Julia Krushkal2, Jianwen Fang2, Dmitriy Sonkin2, Alida Palmisano2, Eric C Polley3, Laura K Fogli3, Mariam M Konaté3, Sarah B Miller3, Melanie A Simpson4, Andrea Regier Voth4, Ming-Chung Li2, Erik Harris1, Xiaolin Wu5, John W Connelly1, Annamaria Rapisarda1, Beverly A Teicher3, Richard Simon2, James H Doroshow6,7.   

Abstract

: The intracellular effects and overall efficacies of anticancer therapies can vary significantly by tumor type. To identify patterns of drug-induced gene modulation that occur in different cancer cell types, we measured gene-expression changes across the NCI-60 cell line panel after exposure to 15 anticancer agents. The results were integrated into a combined database and set of interactive analysis tools, designated the NCI Transcriptional Pharmacodynamics Workbench (NCI TPW), that allows exploration of gene-expression modulation by molecular pathway, drug target, and association with drug sensitivity. We identified common transcriptional responses across agents and cell types and uncovered gene-expression changes associated with drug sensitivity. We also demonstrated the value of this tool for investigating clinically relevant molecular hypotheses and identifying candidate biomarkers of drug activity. The NCI TPW, publicly available at https://tpwb.nci.nih.gov, provides a comprehensive resource to facilitate understanding of tumor cell characteristics that define sensitivity to commonly used anticancer drugs. SIGNIFICANCE: The NCI Transcriptional Pharmacodynamics Workbench represents the most extensive compilation to date of directly measured longitudinal transcriptional responses to anticancer agents across a thoroughly characterized ensemble of cancer cell lines. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30355619      PMCID: PMC6295263          DOI: 10.1158/0008-5472.CAN-18-0989

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

2.  Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Andrew J Wilson; Jeanette Saskowski; Erica Wass; Dineo Khabele
Journal:  Gynecol Oncol       Date:  2014-03-11       Impact factor: 5.482

3.  HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.

Authors:  Esther M de Kruijf; Anita Sajet; Johanna G H van Nes; Russ Natanov; Hein Putter; Vincent T H B M Smit; Gerrit Jan Liefers; Peter J van den Elsen; Cornelis J H van de Velde; Peter J K Kuppen
Journal:  J Immunol       Date:  2010-11-05       Impact factor: 5.422

4.  Strategic design and three-dimensional analysis of antiviral drug combinations.

Authors:  M N Prichard; L E Prichard; C Shipman
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 5.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

6.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Authors:  Philip A Philip; Jacqueline Benedetti; Christopher L Corless; Ralph Wong; Eileen M O'Reilly; Patrick J Flynn; Kendrith M Rowland; James N Atkins; Barry C Mirtsching; Saul E Rivkin; Alok A Khorana; Bryan Goldman; Cecilia M Fenoglio-Preiser; James L Abbruzzese; Charles D Blanke
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

7.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

8.  Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action.

Authors:  Dušica Vidović; Amar Koleti; Stephan C Schürer
Journal:  Front Genet       Date:  2014-09-30       Impact factor: 4.599

9.  Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Authors:  Paolo Ubezio; Francesca Falcetta; Laura Carrassa; Monica Lupi
Journal:  Oncotarget       Date:  2016-03-29

10.  Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment.

Authors:  Julia Krushkal; Yingdong Zhao; Curtis Hose; Anne Monks; James H Doroshow; Richard Simon
Journal:  Clin Epigenetics       Date:  2016-06-24       Impact factor: 6.551

View more
  23 in total

1.  Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Authors:  Dong-Joon Min; Yingdong Zhao; Anne Monks; Alida Palmisano; Curtis Hose; Beverly A Teicher; James H Doroshow; Richard M Simon
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-31       Impact factor: 3.333

2.  Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers.

Authors:  Alberto Martín; Carolina Epifano; Borja Vilaplana-Marti; Iván Hernández; Rocío I R Macías; Ángel Martínez-Ramírez; Ana Cerezo; Pablo Cabezas-Sainz; Maria Garranzo-Asensio; Sandra Amarilla-Quintana; Déborah Gómez-Domínguez; Eduardo Caleiras; Jordi Camps; Gonzalo Gómez-López; Marta Gómez de Cedrón; Ana Ramírez de Molina; Rodrigo Barderas; Laura Sánchez; Susana Velasco-Miguel; Ignacio Pérez de Castro
Journal:  Cell Death Differ       Date:  2022-07-22       Impact factor: 12.067

3.  Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.

Authors:  Junko Murai; Hongliang Zhang; Lorinc Pongor; Sai-Wen Tang; Ukhyun Jo; Fumiya Moribe; Yixiao Ma; Masaru Tomita; Yves Pommier
Journal:  Cell Rep       Date:  2020-03-24       Impact factor: 9.423

4.  Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.

Authors:  David I Quinn; Denice D Tsao-Wei; Przemyslaw Twardowski; Ana M Aparicio; Paul Frankel; Gurkamal Chatta; John J Wright; Susan G Groshen; Stella Khoo; Heinz-Josef Lenz; Primo N Lara; David R Gandara; Edward Newman
Journal:  Invest New Drugs       Date:  2021-01-06       Impact factor: 3.850

5.  Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.

Authors:  Pei-Ming Yang; Li-Shan Lin; Tsang-Pai Liu
Journal:  Biomolecules       Date:  2020-01-09

6.  Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines.

Authors:  Tiannan Guo; Augustin Luna; Vinodh N Rajapakse; Ching Chiek Koh; Zhicheng Wu; Wei Liu; Yaoting Sun; Huanhuan Gao; Michael P Menden; Chao Xu; Laurence Calzone; Loredana Martignetti; Chiara Auwerx; Marija Buljan; Amir Banaei-Esfahani; Alessandro Ori; Murat Iskar; Ludovic Gillet; Ran Bi; Jiangnan Zhang; Huanhuan Zhang; Chenhuan Yu; Qing Zhong; Sudhir Varma; Uwe Schmitt; Peng Qiu; Qiushi Zhang; Yi Zhu; Peter J Wild; Mathew J Garnett; Peer Bork; Martin Beck; Kexin Liu; Julio Saez-Rodriguez; Fathi Elloumi; William C Reinhold; Chris Sander; Yves Pommier; Ruedi Aebersold
Journal:  iScience       Date:  2019-10-31

7.  A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Authors:  Naoko Takebe; Jan H Beumer; Shivaani Kummar; Brian F Kiesel; Afshin Dowlati; Geraldine O'Sullivan Coyne; Richard Piekarz; Lawrence Rubinstein; Laura K Fogli; Ulka Vaishampayan; Sanjay Goel; Cindy L O'Bryant; Bassel F El-Rayes; Vincent Chung; Heinz-Josef Lenz; Richard Kim; Chandra P Belani; Joseph M Tuscano; William Schelman; Nancy Moore; James H Doroshow; Alice P Chen
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

8.  DRIM: A Web-Based System for Investigating Drug Response at the Molecular Level by Condition-Specific Multi-Omics Data Integration.

Authors:  Minsik Oh; Sungjoon Park; Sangseon Lee; Dohoon Lee; Sangsoo Lim; Dabin Jeong; Kyuri Jo; Inuk Jung; Sun Kim
Journal:  Front Genet       Date:  2020-11-12       Impact factor: 4.599

Review 9.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

10.  Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.

Authors:  Julia Krushkal; Simarjeet Negi; Laura M Yee; Jason R Evans; Tanja Grkovic; Alida Palmisano; Jianwen Fang; Hari Sankaran; Lisa M McShane; Yingdong Zhao; Barry R O'Keefe
Journal:  Mol Oncol       Date:  2020-11-24       Impact factor: 7.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.